Open Label Study to Evaluate the Safety Profile and the Quality of Life in Patients Receiving Etanercept for the Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2011

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Etanercept (Primary)
Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
Focus Adverse reactions
Sponsors Wyeth

23 Sep 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
23 Sep 2010 Planned end date changed from 1 Sep 2011 to 1 Jul 2010 as reported by ClinicalTrials.gov.
24 Mar 2010 Planned number of patients changed from 1000 to 909 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com